WAVEMAN · COMPANY

STOK · Stoke Therapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

STOK

Name: Stoke Therapeutics, Inc. (STOK) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Stoke Therapeutics, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001623526

FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$4.3M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

112

13F, latest reported quarter

REVENUE GROWTH

+404.5%

XBRL, annual

NET MARGIN

-3.7%

CONVERSIONS · 180D

codes C/M, not in net · $35.9K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$4.3M over 180 days

-$1.3M over 90 days

below 77% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

112 funds added or opened last quarter

more than 69% of Pharma & Biotech

REVENUE

+404.5% year over year

more than 93% of Pharma & Biotech

MARGIN

-3.7% net margin

more than 62% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$4.3M across 8 people in 180 days.

112 funds added or opened positions in the latest 13F quarter, of 200 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +55.7%

+55.7%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $4.3M sold by insiders over 180 days, 112 funds added last quarter, $841.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Stoke Therapeutics, Inc. insiders sold a net $4.3M of stock across 174 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Ticho Barry

CHIEF MEDICAL OFFICER

SELL

2026-09-01

3,945.0

$120.4K

Ticho Barry

CHIEF MEDICAL OFFICER

SELL

2026-09-01

1,600.0

$49.7K

Allan Jonathan

GENERAL COUNSEL & CORP SEC

SELL

2026-08-18

2,716.0

$86.9K

Allan Jonathan

GENERAL COUNSEL & CORP SEC

SELL

2026-08-18

145.0

$4.7K

Kaye Edward M. MD

Director

SELL

2026-08-18

11,930.0

$381.8K

174 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 169 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Lynx1 Capital Management LP

8,076,808.0 sh

$264.3M

BlackRock, Inc.

5,877,357.0 sh

$192.3M

RTW INVESTMENTS, LP

5,623,525.0 sh

$184.0M

FMR LLC

5,313,100.0 sh

$173.8M

Redmile Group, LLC

3,945,920.0 sh

$129.1M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

BARUCH TICHO

FILED 2026-08-03

$605.1K

BARUCH S. TICHO

FILED 2026-07-01

$236.5K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

First Trust Dow Jones Select MicroCap Index Fund

$5.3M POSITION · AS OF 2026-03-31

2.4%

Franklin Genomic Advancements ETF

$343.1K POSITION · AS OF 2026-03-31

1.6%

Fidelity Disruptive Medicine ETF

$913.1K POSITION · AS OF 2026-02-28

1.5%

ALPS Medical Breakthroughs ETF

$1.9M POSITION · AS OF 2026-02-28

1.3%

Invesco Dorsey Wright Healthcare Momentum ETF

$1.1M POSITION · AS OF 2026-04-30

0.9%

Virtus Biotech Clinical Trials Etf

$278.8K POSITION · AS OF 2026-04-30

0.7%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 3 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

1 ACTIVE

Phase 3

1 ACTIVE

Multi-phase

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$184.4M	$36.6M	$8.8M	$12.4M
OPERATING INCOME	$-20.6M	$-101.4M	$-114.8M	$-104.4M
NET INCOME	$-6.9M	$-89.0M	$-104.7M	$-101.1M
EPS (DILUTED)	-0.12	-1.65	-2.38	-2.60
OPERATING CASH FLOW	$45.6M	$-86.9M	$-81.1M	$-31.9M
CASH	$84.2M	$128.0M	$191.4M	$113.6M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE